Semaglutide + Niacinamide – Injection

(Ship Cold)

Available Dosage Strengths

2.5 mg / 2 mg/mL

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Semaglutide^1-4

Semaglutide, a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA), is an incretin mimetic. Incretins are released from the gastrointestinal tract into the systemic circulation to improve glycemic control. The drug is used for the following indications:

For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise
For the reduction of risk of major adverse cardiovascular events, including reduction of cardiovascular mortality, non-fatal myocardial infarction, or non-fatal stroke, in individuals with established cardiovascular disease and type 2 diabetes mellitus, chronic kidney disease and type 2 diabetes mellitus, or established cardiovascular disease and obesity or who are overweight
For the treatment of obesity and for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity
For the treatment of metabolic dysfunction-associated steatotic liver disease† (MASLD) or metabolic dysfunction-associated steatohepatitis† (MASH) in people with type 2 diabetes mellitus

Niacinamide(vitamin B₃)^5-7

Niacinamide (also known as niacin or nicotinic acid) is a vitamin (vitamin B3) that is an essential nutrient. Niacinamide can be found in bran, yeast, eggs, peanuts, poultry, red meat, fish, whole-grain cereals, legumes, and seeds. It plays a key role in helping the body convert food into energy and protecting against oxidative stress by regulating oxidative enzymes and acting directly as an antioxidant. It is used to treat dermatological diseases, central nervous system diseases, and increased cholesterol levels.

Mechanism of Action

Semaglutide^1-4

Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.

Niacinamide(vitamin B₃)^5-7

Niacinamide contributes to supporting mitochondrial function and metabolic pathways through its conversion to NAD⁺/NADP⁺.It is a vital component in the oxidized state of nicotinamide adenine dinucleotide (NAD, or coenzyme 1) and the reduced form of nicotinamide adenine dinucleotide phosphate (NADP, or coenzyme 2). The coenzymes, NAD and NADP) facilitate essential oxidation-reduction reactions. These coenzymes play key roles in glycolysis, pyruvate metabolism, protein and amino acid metabolism, pentose biosynthesis, glycerol metabolism, synthesis of high-energy phosphate bonds, and fatty acid metabolism.

Adverse Reactions

Common ^1-3

Most adverse reactions are gastrointestinal in nature and dose-dependent:

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite, abdominal pain
Headache, dizziness, and injection site reactions

Contraindications & Precautions

Contraindications:^1-3

Hypersensitivity to semaglutide or glycine or its components
In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2
In patients who are pregnant

Precautions:^1-3

In patients with a history of pancreatitis and gall bladder disease
In patients with renal and hepatic impairment

Storage

Refrigerate at 2–8°C (36–46°F) before and during use. Do not freeze. Protect from light and excessive heat.

References

Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
Niacinamide – Professional Monograph; NatMed Pro ; 2025 ; https://naturalmedicines.therapeuticresearch.com/Data/ProMonographs/Niacinamide
Vitamin B3 StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK526107/ February 29, 2024. Accessed June 26, 2025
Clinical Pharmacology powered by Elsevier (ClinicalKey) – Niacinamide Monograph. https://www.clinicalkey.com

Disclaimer

This information is for educational purposes only. This compounded product has not been reviewed, approved, or evaluated by the Food and Drug Administration for safety and effectiveness. This product is not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding treatment, cure, or prevention of any disease or condition.

This information may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.